CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMT
Drs. Bruce Conklin and Luke Judge will use a $653,000 grant from the CMTA to develop the gene-editing technique known as CRISPR for application to CMT2A, 2E and 2F.
Another $500,000 Pledge to Type 2 Research!
Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000.
New Gene Therapy, Type 1/Type 4 Research Projects Approved
The CMTA today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants cover work on types 1A, 1B and 1X and other demyelinating forms of CMT, including type 4.
The CMT&ME Study: What It’s Like to Live with CMT
There’s been little research to date into how CMT affects
Passage Bio, a genetic medicines company developing AAV-delivered gene therapies, today announced a gene therapy development program for Charcot-Marie-Tooth Neuropathy Type 2A (CMT2A).
$1 Million Gift Pledged to CMT Type 2 Research!
Bob and Gail Buuck are big believers in “impact giving,” They have pledged a $1 million gift to advance CMT Type 2 research.
Type 1 CMT Gene Therapy Project Now Underway
CMTA and MDA Co-Fund Proof-of-Concept Study Using AAV Vector to
CMTA-Funded Research Database Identifies New Mutations
While researchers have identified more than 90 mutated genes that cause CMT, approximately 50 percent of CMT2 patients do not yet have a definitive genetic diagnosis. Dr. Stephan Züchner at the University of Miami is working to change that.
CMTA Announces $1 Million in Funding for STAR Research Projects
April 11, 2019 — The Charcot-Marie Tooth Association today announced
